Navigating a Quiet Revolution: Why Most ADHD Patients Should Stick With What Works Despite a Wave of New Medications
For nearly two decades, clinicians treating Attention-Deficit/Hyperactivity Disorder in the United States lived through a prolonged period of formulation recycling. Pharmaceutical companies routinely took established molecules—primarily amphetamines and methylphenidate—and repackaged…